The following table lists select ratings actions on the debt of an LBO-backed company by either Moody's Investors Service or Standard & Poor's. Action: Arrow:

from 'CC'.

3

9/21/16

9/21/16

9/22/16

9/27/16

9/21/16

9/20/16

9/16/16

Apollo Global

Management

Carlyle Group

Carlyle Group

Cinven

EnCap

Investments

Kravis Roberts

Kohlberg

Quantum

Energy

Partners

& Co.

Claire's Stores.

Foresight Energy

Sequa Corporation

BioClinica Holding

Halcon Resources

Inc.

I.P.

I L.P.

Corp.

Source: Standard & Poor's, Moody's Investors Service and Buyouts

Comstock

Resources Inc.

Basic Energy

Services, Inc.

Highlight: Rating Date Company: Sponsors: Service S&P

Ratings Wrap-Up (September 15, 2016 - September 27, 2016)

9/21/16 Advent Fort Dearborn S&P assigned a 'B-' corporate credit rating and Fort Dearborn is expected to maintain adequate liquidity 3 Holding Co. International stable outlook to Fort Dearborn Holding Co. and credit measures.

> S&P upgraded Foresight's corporate credit rating Foresight completed a restructuring, resolving its to 'B-' from 'D'. The outlook is negative. defaults. However, will continue to face challenges. S&P downgraded Segua's corporate credit rating

to 'CCC' from 'CCC+'. The outlook is negative.

stable outlook to BioClinica Holding.

'B-' from 'D'. The outlook is stable.

rating to 'D' from 'CC'.

S&P assigned a 'B-' corporate credit rating and

S&P upgraded Halcon's corporate credit rating to

S&P raised Comstock's corporate credit rating to

S&P downgraded Basic Energy's corporate credit

'CCC+' from 'SD'. The outlook is negative.

S&P lowered Claire's corporate credit rating to 'SD'

Segua's credit metrics are weak and near-term financial commitments are unstable.

Halcon emerged from bankruptcy with financial

Comstock restructured its debt, but could need

additional restructuring with likely liquidity issues.

BES elected to not make an interest payment and will

need restructuring to meet financial obligations.

restructuring and vastly reduced debt.

its capital structure unsustainable.

BioClinica's revenue is expected to grow, but its leverage will remain high.

Claire's partook in another distressed exchange, leaving

S&P

S&P

S&P

S&P

S&P

S&P

S&P